Physician profile
Thomas Steven Ivan
NPI 1992763411
$4,647.03
in general payments reported to CMS, 2019-2025
40 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,241 · 2020: $692 · 2021: $451 · 2022: $320 · 2023: $230 · 2024: $694 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,943.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $848.91 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $814.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $408.42 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Mylan Specialty L.P. | $240.73 | 2019-2021 | |
| Pfizer INC. | $215.19 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $197.48 | 2024-2025 | Fanapt |
| Genzyme Corporation | $193.76 | 2020-2024 | |
| Supernus Pharmaceuticals, INC. | $172.79 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.56 | 2020-2025 | Xifaxan |
| Amgen INC. | $135.40 | 2019-2025 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.66 | 2020-2025 | Jascayd, Jardiance, Ofev |
| Glaxosmithkline, LLC. | $97.13 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Horizon Therapeutics Plc | $88.90 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.47 | 2019-2020 | |
| Abbvie INC. | $77.31 | 2022-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.